Arcus Biosciences, Inc.

NYSE:RCUS Voorraadrapport

Marktkapitalisatie: US$1.4b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Arcus Biosciences Beheer

Beheer criteriumcontroles 2/4

De CEO Arcus Biosciences' is Terry Rosen, benoemd in May2015, heeft een ambtstermijn van 9.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.12M, bestaande uit 6.4% salaris en 93.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.08% van de aandelen van het bedrijf, ter waarde $ 57.05M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 4.6 jaar.

Belangrijke informatie

Terry Rosen

Algemeen directeur

US$10.1m

Totale compensatie

Percentage CEO-salaris6.4%
Dienstverband CEO9.4yrs
Eigendom CEO4.1%
Management gemiddelde ambtstermijn4.2yrs
Gemiddelde ambtstermijn bestuur4.6yrs

Recente managementupdates

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Sep 23

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15
Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10
Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18
Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 15

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Nov 30
Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08
Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05
Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

May 12
Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

Analyse CEO-vergoeding

Hoe is Terry Rosen's beloning veranderd ten opzichte van Arcus Biosciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$249m

Mar 31 2024n/an/a

-US$231m

Dec 31 2023US$10mUS$650k

-US$307m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$287m

Mar 31 2023n/an/a

-US$279m

Dec 31 2022US$9mUS$350k

-US$267m

Sep 30 2022n/an/a

US$80m

Jun 30 2022n/an/a

US$67m

Mar 31 2022n/an/a

US$58m

Dec 31 2021US$9mUS$367k

US$53m

Sep 30 2021n/an/a

-US$278m

Jun 30 2021n/an/a

-US$199m

Mar 31 2021n/an/a

-US$168m

Dec 31 2020US$6mUS$326k

-US$123m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$112m

Mar 31 2020n/an/a

-US$95m

Dec 31 2019US$2mUS$340k

-US$85m

Sep 30 2019n/an/a

-US$80m

Jun 30 2019n/an/a

-US$69m

Mar 31 2019n/an/a

-US$54m

Dec 31 2018US$1mUS$295k

-US$50m

Sep 30 2018n/an/a

-US$51m

Jun 30 2018n/an/a

-US$63m

Mar 31 2018n/an/a

-US$59m

Dec 31 2017US$427kUS$315k

-US$53m

Compensatie versus markt: De totale vergoeding ($USD 10.12M ) Terry } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Terry is gestegen terwijl het bedrijf verliesgevend is.

CEO

Terry Rosen (64 yo)

9.4yrs

Tenure

US$10,120,945

Compensatie

Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Terry Rosen
Co-Founder9.4yrsUS$10.12m4.08%
$ 57.5m
Juan Jaen
Co- Founder & President9.4yrsUS$4.75m1.56%
$ 22.0m
Robert Goeltz
Principal Financial Officer & CFO4.2yrsUS$3.59m0.017%
$ 238.4k
Jennifer Jarrett
Chief Operating Officer4yrsUS$4.74m0.082%
$ 1.2m
Dimitry Nuyten
Chief Medical Officer2.2yrsUS$3.69m0.022%
$ 311.3k
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Alexander Azoy
VP of Finance & Principal Accounting Officer1.6yrsgeen gegevens0.0032%
$ 45.5k
Jonathan Yingling
Chief Scientific Officer3.8yrsgeen gegevensgeen gegevens
Carolyn Tang
General Counsel & Corporate Secretary6.2yrsUS$2.92m0.052%
$ 738.7k
Holli Kolkey
Vice President of Corporate Communicationsno datageen gegevensgeen gegevens
Yvonne Gehring
Senior Vice President of Human Resources & Operationsno datageen gegevensgeen gegevens
Eric Matthews
Chief Commercial Officer5.3yrsgeen gegevensgeen gegevens

4.2yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RCUS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Terry Rosen
Co-Founder9.5yrsUS$10.12m4.08%
$ 57.5m
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Yasunori Kaneko
Lead Independent Director9.4yrsUS$503.21k0.16%
$ 2.3m
Kathryn Falberg
Independent Director7.1yrsUS$479.08k0.16%
$ 2.3m
Andrew Perlman
Independent Director3.8yrsUS$455.83k0.023%
$ 322.7k
Jeffrey Bluestone
Chairman of Scientific Advisory Boardno datageen gegevensgeen gegevens
C. Machado
Independent Director4.8yrsUS$455.83k0.018%
$ 260.5k
David Lacey
Independent Director & Member of Scientific Advisory Board4.4yrsUS$500.83k0.054%
$ 759.5k
Antoni Ribas
Independent Director & Member of Scientific Advisory Board9.8yrsUS$470.83k0.033%
$ 470.3k
Merdad Parsey
Director4.3yrsgeen gegevensgeen gegevens
Nicole Lambert
Independent Director3.2yrsUS$450.83k0.015%
$ 216.4k
Stefani Spranger
Member of Scientific Advisory Board4.1yrsgeen gegevensgeen gegevens

4.6yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RCUS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).